We are proud to announce that Aisthesis Medical has won the Partnership with the NHS Award at the 2026 Medilink UK National Awards, held on 9th July at Victoria House in London.
This national recognition follows our success at the 2026 SEHTA Healthcare Business Awards, where we won the same category and were subsequently selected to represent the region at the Medilink UK National Awards.
The award reflects the clinical collaboration, NHS engagement, and implementation-focused approach at the heart of VIOSync®, our clinical AI platform for earlier sepsis risk prediction and acute patient deterioration management.
The Medilink UK National Awards celebrate some of the most innovative life sciences and health technology organisations from across the United Kingdom, recognising companies whose work is contributing to improved healthcare delivery, patient outcomes, and industry advancement..
The Results
🏆 National Winner — Partnership with the NHS Award
The Partnership with the NHS category celebrates meaningful collaboration between industry and NHS organisations to improve healthcare services, patient outcomes, or clinical pathways.
For Aisthesis Medical, the award recognises our commitment to developing VIOSync® alongside the clinical, technical, and operational realities of NHS care, not as a standalone AI model, but as a deployable clinical decision-support platform designed for real hospital environments.
What National Recognition Means
Clinical AI does not create value through predictive performance alone.
For an AI platform to reach the bedside, it must integrate with hospital data infrastructure, operate within established clinical workflows, meet stringent regulatory and information-governance requirements, and earn the trust of the professionals expected to use it.
Winning the Partnership with the NHS Award at a national level validates the approach we have taken from the outset: working closely with NHS clinicians, researchers, digital teams, and healthcare stakeholders to ensure that VIOSync® is developed around genuine clinical needs and realistic implementation pathways.
The recognition is particularly meaningful as Aisthesis Medical progresses towards the next phase of clinical validation, regulatory approval, and hospital deployment.
From Regional Recognition to National Winner
Aisthesis Medical qualified for the national awards after winning the Partnership with the NHS category at the 2026 SEHTA Healthcare Business Awards.
Moving from regional recognition to becoming the national category winner represents an important milestone for the company and the wider VIOSync® programme.This national award strengthens our determination to continue building VIOSync® in partnership with healthcare professionals and institutions across the UK and internationally.
About the 2026 Medilink UK National Awards
The Medilink UK National Awards celebrate the achievements of innovative life sciences and healthcare organisations from across the United Kingdom.
The awards bring together regional winners from the Medilink network and recognise excellence across categories including digital healthcare, innovation, NHS partnerships, academic collaboration, sustainability, exports, and outstanding achievement.
The 2026 ceremony was held at Victoria House in London and showcased companies demonstrating a commitment to healthcare innovation, collaboration, and the improvement of health and wellbeing.
Winning the Partnership with the NHS category places Aisthesis Medical among a national group of organisations recognised for developing practical solutions to significant healthcare challenges.
About Aisthesis Medical
Aisthesis Medical is a deep-tech medtech startup developing cutting-edge AI-driven solutions to revolutionize acute care. Founded in 2022, our mission is to save lives by predicting and preventing sepsis before it becomes fatal. Aisthesis Medical is revolutionizing acute care with VIOSync, the first holistic AI-driven digital patient twin platform that goes beyond early sepsis prediction to guide clinical intervention and optimize patient outcomes. VIOSync, predicts sepsis up to 48 hours earlier, integrates directly into hospital workflows, and optimizes treatment pathways to reduce unnecessary antibiotic use.
Want to Learn More or Partner With Us?
If you’re a hospital, NHS trust, or healthcare investor interested in learning more about VIOSync or our security and compliance posture, we’d love to connect.
📩 Get in touch: https://aisthesismed.com/contact/
🌐 Learn more about VIOSync: https://aisthesismed.com/product/